0.5 semaglutide (Ozempic/Wegovy) shows 3-year efficacy for blood sugar control and weight loss WEGOVY(SEMAGLUTIDE) 0.5MG - AceCosm
Description
Results demonstrated dose-dependent MASH resolution without worsening fibrosis in 51.8%, 62.8%, and 73.3% of participants taking 5mg, 10mg, and 15mg doses respectively, versus merely 13.2% with placebo
[DOI] [PubMed] [Google Scholar] 24.stergaard L., Frandsen C
doi: 10.1111/liv.12120 24 RasmussenCBLindenbergS
These products are not intended to diagnose, treat, cure, or prevent any disease and are not approved for clinical, diagnostic, or therapeutic applications
Any use outside of authorised clinical trials would be unlicensed and is not recommended
